Welcome to our dedicated page for REGENEREX PHARMA SEC filings (Ticker: RGPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REGENEREX PHARMA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REGENEREX PHARMA's regulatory disclosures and financial reporting.
REGENEREX PHARMA, INC. (RGPX) reports that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 has been completed and filed, but after the applicable deadline. Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 remain unfiled and are delinquent, and the company did not submit Notifications of Late Filing on Form 12b-25 for these periods. Management describes substantial additional accounting, reconciliation, and review work undertaken to complete the 2025 Form 10-K and to prepare the outstanding quarterly financial statements, and states it is working with internal staff and external advisors to become current in SEC reporting as promptly as practicable. The company states it does not currently anticipate changes to its operations or business strategy due to the filing delays but cautions that financial information for the affected quarters is incomplete and should be evaluated together with other SEC filings.
Regenerex Pharma, Inc. (RGPX) is a Nevada-based wound-care company focused on proprietary technologies for chronic and acute wounds, centered on its QBx™ platform and primary product, Accelerex™. Regenerex targets diabetic ulcers, pressure ulcers, burns and surgical wounds and highlights clinical data it states show high closure rates in non‑healing chronic wounds.
For the nine months ended December 31, 2025, the company generated no revenue and reported a net loss of $2,543,211, similar to the $2,527,041 loss for the year ended March 31, 2025. Cash declined to $11,049 from $653,025, while current liabilities reached $5,169,186, resulting in a stockholders’ deficit of $5,001,304. The auditor and management disclose substantial doubt about Regenerex’s ability to continue as a going concern.
Operations have been funded by equity sales and related‑party and other notes payable; the company is seeking an additional $5,000,000 by September 2026. A March 2025 bank account hack led to a theft of funds, with partial recovery and a bank settlement recorded. Regenerex changed its fiscal year end to December 31 and discloses multiple related‑party arrangements, including an asset purchase with up to $10,000,000 contingent consideration and significant notes payable to related parties. The company reports new litigation it has initiated against its former CFO and a related entity, with outcomes not yet determined.
Regenerex Pharma, Inc. placed its Chief Financial Officer, Kenneth Perry, on paid administrative suspension leave effective March 31, 2026, after the Board cited concerns about compliance with Board directives, financial oversight, corporate governance, and the company’s financial reporting processes and internal controls. The company states that these matters are under review and that no final determinations have been made. Mr. Perry remains an employee and continues to receive his base salary and benefits. Effective April 1, 2026, the Board appointed Don E. Ray as Interim Chief Financial Officer on a 90-day initial term with an interim salary of $150,000 annually, bringing extensive public-company auditing and automotive industry financial leadership experience.
Regenerex Pharma, Inc. notified the SEC on Form 12b-25 that it cannot timely file its Form 10-K for the period ended December 31, 2025. The delay is due to an ongoing internal review initiated by independent board members and required coordination with external auditors and legal counsel. Auditors have advised they cannot complete audit procedures until sufficient progress in the review is made. The company states the review may lead to adjustments to previously reported financial information but cannot reasonably estimate any magnitude. The registrant intends to file the Form 10-K as soon as practicable after the review and audit work are completed.
Regenerex Pharma, Inc. reported no revenue for the six months ended September 30, 2025 and a larger net loss of $1,477,596, compared with $802,132 a year earlier. Higher research and development, payroll, lease and IT expenses drove the increased loss. Cash and equivalents fell sharply to $11,659 from $653,025, while total assets were $617,764 and total liabilities $5,316,564, resulting in a stockholders’ deficit of $4,698,800. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern and is seeking additional capital through equity and debt financing. During the period, Regenerex raised $500,000 by issuing 500,000 shares at $1.00 per share with matching warrants and adopted a 2025 equity plan with 20 million shares, including 4,000,000 options granted to the CFO. The company is developing advanced wound care products and expects to launch sales in the quarter ending December 31, 2025.
Regenerex Pharma, Inc. filed a Form 12b-25 to notify a late filing of its Form 10-Q for the quarter ended September 30, 2025. The company explains that it could not complete the quarterly report on time due to unanticipated delays in compiling and reconciling financial data, including additional time needed to obtain and verify information from third-party service providers.
Regenerex states that the Form 10-Q will be filed within the allowed extension period, which for a quarterly report is up to five calendar days after the original due date. The company confirms that all other required periodic reports over the past 12 months have been filed and indicates it does not anticipate any significant change in results of operations compared with the same quarter of the prior year.
Regenerex Pharma (RGPX) changed its fiscal year end to December 31. The Board approved moving the company’s fiscal year end from March 31 to December 31. To bridge the shift, the company will file a transition report on Form 10-K covering the period from April 1, 2025 through December 31, 2025.
This is an administrative change to align reporting periods. The upcoming transition 10-K will provide financials for the nine-month period noted before the new annual cycle begins on a calendar-year basis.